EGFR and lung adenocarcinoma: The efficacy and safety of EGFR-TKIs alone versus EGFR-TKIs plus chemotherapy for treatment of advanced lung adenocarcinoma with EGFR 19Del, L858R mutation still needs to be further investigated in large prospective clinical trials.